Study study type PathologyT1T0Patientssample sizesROB Results

mGC or mGEJC - L1 - HER2 neg/PDL1 positive metastatic/advanced mGC or mGEJC mGC or mGEJC - 1st line (L1) mGC or mGEJC - L1 - HER2 neg/PDL1 positive

versus Standard of Care (SoC)
nivolumab plus SoC
CheckMate 649 (PDL1 CPS>5), 2021
  NCT02872116
RCTmGC or mGEJC - L1 - HER2 neg/PDL1 positivenivolumab plus chemotherapyICC (XELOX, FOLFOX)previously untreated, non-HER2-positive, advanced or metastatic gastric cancer, GEJ cancer or esophageal adenocarcinoma, only patients with PDL1 CPS>5473 / 482some concern
conclusif
  • demonstrated 29 % decrease in deaths (OS) (PE)
  • demonstrated 32 % decrease in progression or deaths (PFS) (PE)
CheckMate 649 (PDL1 CPS>1), 2021
  NCT02872116
RCTmGC or mGEJC - L1 - HER2 neg/PDL1 positivenivolumab plus chemotherapyICC (XELOX, FOLFOX)previously untreated, non-HER2-positive, advanced or metastatic gastric cancer, GEJ cancer or esophageal adenocarcinoma, only patients with PDL1 CPS>1641 / 655some concern
conclusif
  • demonstrated 23 % decrease in deaths (OS) (PE)
  • suggested 26 % decrease in progression or deaths (PFS)

mGC or mGEJC - L1 - HER2 negative metastatic/advanced mGC or mGEJC mGC or mGEJC - 1st line (L1) mGC or mGEJC - L1 - HER2 negative

versus Standard of Care (SoC)
nivolumab plus SoC
CheckMate 649, 2021
  NCT02872116
RCTmGC or mGEJC - L1 - HER2 negativenivolumab plus chemotherapyICC (XELOX, FOLFOX)previously untreated, non-HER2-positive, advanced or metastatic gastric cancer, GEJ cancer or esophageal adenocarcinoma789 / 792some concern
conclusif
  • demonstrated 20 % decrease in deaths (OS) (PE)
  • suggested 23 % decrease in progression or deaths (PFS)

mGC or mGEJC - L1 - PDL1 positive metastatic/advanced mGC or mGEJC mGC or mGEJC - 1st line (L1) mGC or mGEJC - L1 - PDL1 positive

versus placebo plus SoC
pembrolizumab alone
KEYNOTE-062 (P vs C ; CPS>10), 2020
  NCT02494583
RCTmGC or mGEJC - L1 - PDL1 positivepembrolizumabplacebo plus chemotherapy (cisplatin plus fluorouracil or capecitabine)first-line treatment for participants with advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma (PDL1 CPS>10)92 / 90some concern
suggested
  • suggested 31 % decrease in deaths (OS),deaths (OS) (PE)
pembrolizumab plus SoC
KEYNOTE-062 (PC vs C ; CPS>1), 2020
  NCT02494583
RCTmGC or mGEJC - L1 - PDL1 positivepembrolizumab plus 5FU or capcitabine plus cisplatineplacebo plus 5FU or capcitabine plus cisplatinefirst-line treatment for participants with advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma257 / 250low
inconclusive
  • inconclusive 15 % decrease in deaths (OS),deaths (OS) (PE)
  • inconclusive 16 % decrease in progression or deaths (PFS),progression or deaths (PFS) (PE)
KEYNOTE-062 (PC vs C ; CPS>10), 2020
  NCT02494583
RCTmGC or mGEJC - L1 - PDL1 positivepembrolizumab plus chemotherapy (5FU or capecitabine, plus cisplatine)placebo plus chemotherapy (5FU or capecitabine, plus cisplatine)first-line treatment for participants with advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma (PDL1 CPS>10)99 / 90low
suggested
  • inconclusive 15 % decrease in deaths (OS),deaths (OS) (PE)
versus Standard of Care (SoC)
pembrolizumab alone
KEYNOTE-062 (P vs C ; CPS>1), 2020
  NCT02494583
RCTmGC or mGEJC - L1 - PDL1 positivepembrolizumabplacebo plus chemotherapy (5FU or capecitabine plus cisplatin)first-line treatment for participants with advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma256 / 250some concern
inconclusive
  • statistically significant 66 % increase in progression or deaths (PFS),progression or deaths (PFS)
  • statistically significant 71 % decrease in objective responses (ORR),objective responses (ORR)